

CURRICULUM VITAE
David Henry Jablonski, M.D.



Winter Park Urology Associates, P.A.
Urological Ambulatory Surgery Center, Inc.

**1812 North Mills Avenue
Orlando, FL 32803**

PERSONAL: Date of Birth: February 17, 1966
Place of Birth: Grosse Pointe, Michigan
Married: Janet Holder Jablonski, M.D. - Family Medicine

EDUCATION: **University of Florida College of Medicine, Gainesville, Florida**
Division of Urology Residency Training Program
July 1994-June 1997

University of Florida College of Medicine, Gainesville, Florida
Department of Surgery, General Surgery Residency Training Program
July 1992-June 1994

University of Florida College of Medicine, Gainesville, Florida
Doctor of Medicine - 1988-1992

University of Virginia, Charlottesville, Virginia
Bachelor of Arts in Biology - 1984-1988

WORK EXPERIENCE: **Winter Park Urology Associates**
July 1997 - Present

ACADEMIC APPOINTMENTS: Associate Clinical Professor of Surgery
University of Florida
Division of Urology

Clinical Assistant Professor
Florida State University School of Medicine
Department of Clinical Sciences

CERTIFICATION: American Board of Urology, February 1999
Diplomat of National Board of Medical Examiners, July 1993
Florida Board of Medicine #ME0065714

PROFESSIONAL SOCIETIES: Florida Urologic Society
American Urologic Association
American Medical Association
Florida Medical Association

RESEARCH: "A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of XXXX for the Prevention of Prostate Cancer in Men with High Grade Prostate Intraepithelial Neoplasia"
2005-present

"A Multicenter, 2 Week, Double-Blind Study of XXXX 60mg QD Modified Release Capsules and Placebo Given Once Daily In The Morning or In The Evening In Patients With Overactive Bladder"
2005-present

"A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of The Withdrawal Effects of Chronic Daily and As Needed Dosing with Study Drug in the Treatment of Premature Ejaculation" 2005-present

"Prospective, Observational Registry and Patient Survey of the Management of Men with Symptomatic Benign Prostatic Hyperplasia" 2004-present

"An Open-Label, Multicenter Study To Assess the Efficacy and

Safety of Daily Oral Administration of 5 and 10mg Study Drug in Patients Who Wish to Switch from Detrol LA® for the Treatment of Overactive Bladder Symptoms” 2004-present

“A Randomized, Double-Blind, Crossover Study to Evaluate the Duration of Erection following Study Drug 10mg Administration

For 4 Weeks in a Fixed-Dose Regimen Compared to Placebo In Males with ED” 2004-present

“A Double-Blind, Randomized, Placebo-Controlled Trial of Elmiron® For the Treatment of Chronic, Non-Bacterial Prostatitis” 2004-present

“A Study to Compare the Safety and Efficacy of Once Daily Study Drug Versus Twice Daily Study Drug in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis” 2004-present

“Study of Study Drug in Women of Different Demographic Characteristics and Co-morbidities with Stress Urinary Incontinence: Evaluation of Efficacy and Safety” 2004-present

“A Phase 3, Parallel Group, Randomized, Double-Blind, Placebo Controlled Multicenter Trial to Investigate the Efficacy, Tolerability And Safety of Study Drug Sustained Release in Subjects with Overactive Bladder Syndrome” 2003-present

“A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of Study Drug for the Prevention of Bone Fractures in Men with Prostate Cancer on Androgen Deprivation Therapy” 2003-present

“A Double-Blind, Placebo-Controlled Study of Frequency and Urgency Using Study Drug 20mg Tablets, Twice Daily, For 12 Weeks Followed by a 6-Month Open-Label Treatment Phase in Patients with Overactive Bladder” 2003-2004

A Multicenter, Open-Label, Flexible Dose Study to Investigate the Use Patterns of Viagra® (sildenafil citrate) And The Ability of Investigators To Further Optimize Subject Satisfaction With Viagra® Through Customized Instruction” 2003-present

“Open-Label Study of the Efficacy and Safety of 5mg and 10mg Study Drug in Patients with Overactive Bladder Symptoms” 2003-2004

“An Open-Label Study to Evaluate the Efficacy and Safety of Study Drug Administered ‘On Demand’ to Men of Various Populations with Erectile Dysfunction” 2003-2004

“A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety and Reliability of 20mg Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects with Erectile Dysfunction and a Demonstrated Successful First Response to 20mg Vardenafil” 2003-2004

“A Double-Blind, Placebo-Controlled, Randomized US/Latin America Study to Evaluate the Effect of Study Drug Prolonged Release on Nocturia in Patients with Symptoms of Overactive Bladder (OAB)” 2003-2003

“A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Study Drug 0.5mg Administered Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer” 2003-present

“A Phase 3B, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of XXXXX in Subjects with Overactive Bladder” – 2002-2003

“A Multicenter, Phase IIb, Four Arm, Dose Finding, Randomized, Placebo-Controlled Study to Determine the Long Term Prostate Cancer Chemoprevention Efficacy and Safety of 20mg, 40mg & 60mg Daily of XXXXX in Men with High Grade Prostate Intraepithelial Neoplasia (PIN)” – 2001-2004

"An Open-Label, Multicenter, Multinational Study to Determine the Safety and Efficacy of XXXXX Oral Solution in Children with Symptoms of Urge Urinary Incontinence Suggestive of Detrusor Instability" – 2002-2003

"An Open-label Trial on the Effect of I.V. XXXXX 4mg on Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients with Bone Metastasis" – 2002-2003

"A Randomized, Double-Blind, Parallel Group, Multi-center Study to Investigate the Time to Onset of Action of 20mg of XXXXX Compared to Placebo in Males with Erectile Dysfunction" 2002-2002

"A phase III, Randomized, Multicenter, Placebo-Controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of Study Drug for the Treatment of Hot Flashes Following Surgical or Chemical Castration of Prostate Cancer Patients and Its Impact on the Quality of Life in These Patients." 2001 - 2003

"A Phase IV, Open-label, Multi-Center, Large Community Based Study with an Eight Week Treatment Period to Evaluate the Satisfaction and Experience with Replacement Therapy" 2000-2001

"A Phase IV, Open-Label, Multicenter, Community-Based Trial of Study Drug for the Treatment of Urogenital Symptoms in Postmenopausal Women" 2000 - 2001

"A Patient Acceptability Study of a Once-Daily Formulation of Study Drug. A Phase IIIB, Open-Label, Single-Arm Trial in Adult Patients With Overactive Bladder and Symptoms of Urinary Frequency, Urgency, and/or Urge Incontinence." 2000 - 2001

"A Multicenter Trial of Induction and 6 Courses of 3 Week Maintenance With BCG Versus BCG Plus Interferon Alfa-2B (Intron A) In Superficial Bladder Cancer" 2001 - 2001

"A Multi-center, Multinational Open Clinical Study to Explore Relationships between Genotypic (from DNA) and Serologic (from serum) Findings and Phenotypic Manifestations in a Large Cohort of Participants" 2001 - 2001

"A Phase IIb/III Chemoprevention Trial of Study Drug to Prevent the Recurrence of Superficial Bladder Cancer" 2001 - 2002

"Prospective, Randomized, Double-Blind Multi-Center, Fixed Dose, Parallel-Group Twelve Month Extension of Study XXXXX to Investigate the Safety and Tolerability of the Study Drug in the Treatment of Patients with Erectile Dysfunction over a Total Exposure Time of 24 Months" – 2001 - 2002

"A Phase III, Double-Blind, Randomized, Parallel Study Evaluating the Safety and Efficacy of Study Drug in the Treatment of Male Erectile Dysfunction" 2001-2002

"A Double-Blind, Placebo Controlled Study of Sustained Release Study Drug in Subjects with Symptoms of Overactive Bladder of Urgency, Frequency and Urinary Incontinence" - 2001 - Present

"An Investigation Of The NMP22 Point of Care (POC) Device As An Aid In The Monitoring Of Bladder Cancer Patients." 2001- 2002

"An Investigation Of The NMP22 Point Of Care (POC) Device As An Aid In The Screening Of Patients At Risk For Bladder Cancer. 2001 - 2002

"A Randomized, Double-Blind, Multi-Centre, Fixed Dose, Parallel-Group Twelve Month Study to Investigate the Safety and Tolerability of a Study Drug in the Treatment of Patients with Erectile Dysfunction" - 2000 – 2001

"A Phase III at Home Use Study Evaluating the Efficacy and Safety of Escalating Doses of Study Drug 2, 3, and 4 mg in the Treatment with Erectile Dysfunction" 1999 – 2001

"A Study to Evaluate the Efficacy and Safety of a Study Drug Versus Placebo in Subjects with Overactive Bladder" - 1999 – 2001

"A Phase III, Multi-Center, Double-Blind, Randomized, Placebo

Controlled, Parallel Group Study of the Efficacy and Safety of a Controlled Release Study Drug Versus A Study Drug in the

Treatment of Subjects with Overactive Bladder" - 1999 – 2001

"A Randomized, Parallel Group, Double-Blind, Placebo-Controlled Study Comparing the Safety, Tolerance, and Efficacy of a Study Drug in Patients with Detrusor Hyperreflexia" - 1999 – 2000

"A Phase III, Long-Term, Open-Label, Flexible Dose, and Safety Extension Study of Study Drug in the Treatment of Male Erectile Dysfunction" - 1998 – 1999

"A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of Study Drug 0.5 Mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia" - 1997 – 2001

"A Phase III Efficacy and Safety Study Comparing Escalating Doses of Study Drug to 5 mg or 6 mg Doses of Study Drug or Placebo in the Treatment of Male Erectile Dysfunction" – 1997 -1998

"A Study to Evaluate the Impact of Study Drug on Treatment Satisfaction" - 1997 – 1998

PRESENTATIONS/ PUBLICATIONS

"Transurethral Vapertrode Electro vaporization of the Prostate (TUEVP); Physical Principles, Techniques and Results".
Submitted to 1997 Southeastern Section and 1997 AUA.

"Pediatric Hemorrhagic Cystitis: The University of Florida Experience".
Presented at the Florida Residence Meeting, San Juan, Puerto Rico, January 1996.